BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 22215016)

  • 21. Expression of human Wiskott-Aldrich syndrome protein in patients' cells leads to partial correction of a phenotypic abnormality of cell surface glycoproteins.
    Huang MM; Tsuboi S; Wong A; Yu XJ; Oh-Eda M; Derry JM; Francke U; Fukuda M; Weinberg KI; Kohn DB
    Gene Ther; 2000 Feb; 7(4):314-20. PubMed ID: 10694812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models.
    Marangoni F; Bosticardo M; Charrier S; Draghici E; Locci M; Scaramuzza S; Panaroni C; Ponzoni M; Sanvito F; Doglioni C; Liabeuf M; Gjata B; Montus M; Siminovitch K; Aiuti A; Naldini L; Dupré L; Roncarolo MG; Galy A; Villa A
    Mol Ther; 2009 Jun; 17(6):1073-82. PubMed ID: 19259069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
    Boztug K; Dewey RA; Klein C
    Curr Opin Mol Ther; 2006 Oct; 8(5):390-5. PubMed ID: 17078381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector.
    Horino S; Uchiyama T; So T; Nagashima H; Sun SL; Sato M; Asao A; Haji Y; Sasahara Y; Candotti F; Tsuchiya S; Kure S; Sugamura K; Ishii N
    PLoS One; 2013; 8(8):e71594. PubMed ID: 23990961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of migratory defects in a murine model of Wiskott-Aldrich syndrome gene therapy.
    Blundell MP; Bouma G; Calle Y; Jones GE; Kinnon C; Thrasher AJ
    Mol Ther; 2008 May; 16(5):836-44. PubMed ID: 18388921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
    Labrosse R; Chu JI; Armant MA; Everett JK; Pellin D; Kareddy N; Frelinger AL; Henderson LA; O'Connell AE; Biswas A; Coenen-van der Spek J; Miggelbrink A; Fiorini C; Adhikari H; Berry CC; Cantu VA; Fong J; Jaroslavsky J; Karadeniz DF; Li QZ; Reddy S; Roche AM; Zhu C; Whangbo JS; Dansereau C; Mackinnon B; Morris E; Koo SM; London WB; Baris S; Ozen A; Karakoc-Aydiner E; Despotovic JM; Forbes Satter LR; Saitoh A; Aizawa Y; King A; Nguyen MAT; Vu VDU; Snapper SB; Galy A; Notarangelo LD; Bushman FD; Williams DA; Pai SY
    Blood; 2023 Oct; 142(15):1281-1296. PubMed ID: 37478401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome.
    Catucci M; Prete F; Bosticardo M; Castiello MC; Draghici E; Locci M; Roncarolo MG; Aiuti A; Benvenuti F; Villa A
    Gene Ther; 2012 Dec; 19(12):1150-8. PubMed ID: 22189416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wiskott-Aldrich syndrome.
    Notarangelo LD; Miao CH; Ochs HD
    Curr Opin Hematol; 2008 Jan; 15(1):30-6. PubMed ID: 18043243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in foamy virus vector technology and disease correction could speed the path to clinical application.
    Verhoeyen E
    Mol Ther; 2012 Jun; 20(6):1105-7. PubMed ID: 22652999
    [No Abstract]   [Full Text] [Related]  

  • 30. Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences.
    Martín F; Toscano MG; Blundell M; Frecha C; Srivastava GK; Santamaría M; Thrasher AJ; Molina IJ
    Gene Ther; 2005 Apr; 12(8):715-23. PubMed ID: 15750617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficient transcriptional targeting of human hematopoietic stem cells and blood cell lineages by lentiviral vectors containing the regulatory element of the Wiskott-Aldrich syndrome gene.
    Leuci V; Gammaitoni L; Capellero S; Sangiolo D; Mesuraca M; Bond HM; Migliardi G; Cammarata C; Aglietta M; Morrone G; Piacibello W
    Stem Cells; 2009 Nov; 27(11):2815-23. PubMed ID: 19785032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of lentiviral gene therapy for Wiskott Aldrich syndrome.
    Galy A; Roncarolo MG; Thrasher AJ
    Expert Opin Biol Ther; 2008 Feb; 8(2):181-90. PubMed ID: 18194074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current and emerging treatment options for Wiskott-Aldrich syndrome.
    Worth AJ; Thrasher AJ
    Expert Rev Clin Immunol; 2015; 11(9):1015-32. PubMed ID: 26159751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency.
    Bauer TR; Tuschong LM; Calvo KR; Shive HR; Burkholder TH; Karlsson EK; West RR; Russell DW; Hickstein DD
    Mol Ther; 2013 May; 21(5):964-72. PubMed ID: 23531552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome.
    Hacein-Bey Abina S; Gaspar HB; Blondeau J; Caccavelli L; Charrier S; Buckland K; Picard C; Six E; Himoudi N; Gilmour K; McNicol AM; Hara H; Xu-Bayford J; Rivat C; Touzot F; Mavilio F; Lim A; Treluyer JM; Héritier S; Lefrère F; Magalon J; Pengue-Koyi I; Honnet G; Blanche S; Sherman EA; Male F; Berry C; Malani N; Bushman FD; Fischer A; Thrasher AJ; Galy A; Cavazzana M
    JAMA; 2015 Apr; 313(15):1550-63. PubMed ID: 25898053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency.
    Trobridge GD; Beard BC; Wu RA; Ironside C; Malik P; Kiem HP
    PLoS One; 2012; 7(9):e45173. PubMed ID: 23028826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical aspects and molecular analysis of Chinese patients with Wiskott-Aldrich syndrome in Taiwan.
    Lee WI; Yang CY; Jaing TH; Huang JL; Chien YH; Chang KW
    Int Arch Allergy Immunol; 2008; 145(1):15-23. PubMed ID: 17703096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A peptide derived from the Wiskott-Aldrich syndrome (WAS) protein-interacting protein (WIP) restores WAS protein level and actin cytoskeleton reorganization in lymphocytes from patients with WAS mutations that disrupt WIP binding.
    Massaad MJ; Ramesh N; Le Bras S; Giliani S; Notarangelo LD; Al-Herz W; Notarangelo LD; Geha RS
    J Allergy Clin Immunol; 2011 Apr; 127(4):998-1005.e1-2. PubMed ID: 21376381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A possible turning point in the hematopoietic stem cell gene therapy for primary immunodeficiency diseases? Lentiviral vectors could take the place of retroviral vectors.
    Ariga T
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1015-8. PubMed ID: 24168409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene therapy for Wiskott-Aldrich Syndrome.
    Bosticardo M; Ferrua F; Cavazzana M; Aiuti A
    Curr Gene Ther; 2014; 14(6):413-21. PubMed ID: 25245089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.